• Corpus ID: 14126146


  author={Ann K. Morrison and Constantine G Lyketsos},
The pathophysiology of Alzheimer’s disease (AD) is complex, involving several neurotransmitter systems and pathophysiologic processes. The 3 hallmarks of AD—β-amyloid plaques, neurofibrillar y tangles, and neuronal cell death—are well known and central factors in AD pathology. These hallmarks, combined with our information on neurotransmitter involvement, are specific to AD based on the timing, sequence, and location of these changes. This article reviews the pathophysiology and course of brain… 
Alzheimer’s disease, Epidemiology, causes, diagnosis and novel treatments: A review.
This review reveals current innovations in pathology, diagnosis and novel treatment options for Alzheimer’s disease and exposes modern treatments options for AD (immunotherapy, cell transplantation and gene therapy).
Neuroprotective effects of resveratrol in Alzheimer's disease.
Resveratrol was able to decrease the expression of amyloid precursor protein, along with improvement of spatial working memory, and since RSV acts as an antioxidant, it can be safely used as oral drug.
A Review on PPARγ- A Novel Therapeutic Target for Alzheimer's Disease
Alzheimer’s disease (AD) is the most common form of neurodegenerative disorder with dementia in the elderly and the number of affected individuals after the age of 60, rising from a prevalence of 1%
up in arms against alzheimers disease
There is no definite cure for AD, but treatment by two types of drugs is currently used to allay cognitive symptoms, one type is cholinesterase inhibitors and second type is glutamatergic partial antagonist.
Therapeutic role of rifampicin in Alzheimer's disease
Beyond suggesting that rifampicin shows strong brain protective effects in preclinical models of Alzheimer's disease, this work provides substantial clinical evidence for the neuroprotective and pro‐cognitive effects of rifampsicin.
Effect of Thymoquinone against Aluminum Chloride-Induced Alzheimer-Like Model in Rats: A Neurophysiological and Behavioral Study
TQ could mitigate the neurodegenerative markers and oxidative stress indices encountered in AD, presumably via its antioxidant and anti-inflammatory effects.
Zanthoxylum alatum ameliorates scopolamine-induced amnesia in rats: Behavioral, biochemical, and molecular evidence
Zanthoxylum alatum seeds could probably counteract amnesia and its use is mainly reported as a stimulant and tonic, this novel activity could be a boon for the scientists to explore more in this direction.
Amelioration of Scopolamine-Induced Amnesic, Anxiolytic and Antidepressant Effects of Ficus benghalensis in Behavioral Experimental Models
Methanolic extract of F. benghalensis bark furnished scientific proof behind folkloric claims of the memory improving, anxiety-reducing and depression-resolving characteristics of the plant.
Brain Training Improves Cigarette Smoke Induced Dementia in Female C57 Black 6 Mice
The results indicated that brain training significantly decreased the deleterious effects of cigarette smoke in hippocampus tissue and improved dementia symptoms.


Emerging prospects for the disease-modifying treatment of Alzheimer's disease.
Cholesterol and apolipoprotein E in Alzheimer's disease
  • A. Reiss
  • Biology
    American journal of Alzheimer's disease and other dementias
  • 2005
Cholesterol has been demonstrated to modulate processing of APP to Aβ, a proteolytically derived product of amyloid precursor protein (APP), and high levels of cholesterol are associated with increased risk of AD.
Inflammation and Alzheimer’s disease
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
It has been more than 10 years since it was first proposed that the neurodegeneration in Alzheimer's disease (AD) may be caused by deposition of amyloid β-peptide in plaques in brain tissue and the rest of the disease process is proposed to result from an imbalance between Aβ production and Aβ clearance.
Vitamin E in Neurodegenerative Disorders: Alzheimer's Disease
The data suggest that vitamin E may be effective against in vivo oxidation of CSF lipoproteins and brain lipids, and offer new perspectives in the treatment of AD and other neurodegenerative disorders.
Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.
Atorvastatin treatment may be of some clinical benefit and could be established as an effective therapy for Alzheimer disease if the current findings are substantiated by a much larger multicenter trial.
Oxidative imbalance in alzheimer’s disease
The evidence for oxidative stress in Alzheimer’s disease and its likely sources and consequence in relation to other pathological changes is presented and could provide some protective mechanism to reduce oxidative stress and ensure that neurons do not rapidly succumb to oxidative insults.
Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease
Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer’s disease
The data suggest that loss of neocortical 5-HT2A receptors may predict for faster cognitive decline in AD, and point to serotomimetics as potentially useful adjuvants to cholinergic replacement therapies.